BrightSpring Q3 2026 earnings: revenue hits $4.21B

Pharmacy Solutions recorded $340.86 in revenue per script and $28.86 in gross profit per script during the quarter.

Rhea-AI Filing Summary

BrightSpring Health Services, Inc. (BTSG) reported third-quarter 2026 revenue of $4.213234 billion, compared with $3.334106 billion for the quarter ended September 30, 2025. Income from continuing operations was $100.802 million, versus $37.488 million. Adjusted EBITDA, a non-GAAP measure, was $227.759 million, up 42% from $160.443 million.

BrightSpring increased full-year 2026 revenue guidance to $15,900 million to $16,125 million and Adjusted EBITDA guidance to $850 million to $860 million. The ranges represent revenue growth of 23.2% to 24.9% and Adjusted EBITDA growth of 37.6% to 39.3% compared with full-year 2025 results excluding Community Living. The guidance also excludes the effects of future closed acquisitions.

Operating cash flow was $204.322 million, compared with $107.936 million in Q3 2025. Pharmacy Solutions dispensed 10,949,875 prescriptions versus 10,793,219 a year earlier, while Home Health Care average daily census was 47,256 versus 29,980. The Amedisys and LHC branches acquisition is expected to contribute approximately $35 million in 2026 Adjusted EBITDA.

5 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Full-year 2026 guidance increased to $15,900 million to $16,125 million in revenue and $850 million to $860 million in Adjusted EBITDA.
• Moderate pointQ3 revenue: $4.213234 billion, versus $3.334106 billion in 2025.
• Moderate pointQ3 income from continuing operations: $100.802 million, versus $37.488 million.
• Moderate pointQ3 Adjusted EBITDA: $227.759 million, up 42% from $160.443 million.
• Moderate pointQ3 operating cash flow: $204.322 million, versus $107.936 million in 2025.

Negative

• None.

Filing Explained

BrightSpring reported 198,814,320 common shares issued and outstanding at September 30, 2026, versus 192,124,125 at December 31, 2025. For a holder whose share count did not change, the higher total share count reduces that holder’s percentage ownership, absent offsetting changes.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Q3 revenue: $4.213234 billion Income from continuing operations: $100.802 million Adjusted EBITDA: $227.759 million +5 more

8 metrics

Q3 revenue $4.213234 billion Three months ended September 30, 2026; $3.334106 billion in Q3 2025

Income from continuing operations $100.802 million Three months ended September 30, 2026; $37.488 million in Q3 2025

Adjusted EBITDA $227.759 million Three months ended September 30, 2026; $160.443 million in Q3 2025; 42% growth

Cash provided by operating activities $204.322 million Three months ended September 30, 2026; $107.936 million in Q3 2025

Full-year revenue guidance $15,900 million to $16,125 million 2026 guidance; 23.2% to 24.9% growth compared with full-year 2025 results excluding Community Living

Full-year Adjusted EBITDA guidance $850 million to $860 million 2026 guidance; 37.6% to 39.3% growth compared with full-year 2025 results excluding Community Living

Expected Adjusted EBITDA contribution Approximately $35 million Expected from the Amedisys and LHC branches acquisition in 2026

Revenue per script $340.86 per script Pharmacy Solutions, three months ended September 30, 2026; $274.89 in Q3 2025

Key Terms

Adjusted EBITDA, non-GAAP financial measures, gross profit per script, average daily census

4 terms

Adjusted EBITDA financial

"Total Adjusted EBITDA of $850 million to $860 million"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

non-GAAP financial measures financial

"This press release contains “non-GAAP financial measures”"

Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.

gross profit per script financial

"Gross Profit per script ($)"

average daily census financial

"Home Health Care average daily census"

The average daily census is the average number of patients occupying beds in a hospital or healthcare facility each day over a set period. Like a hotel’s average number of guests, it shows how fully a facility is being used and matters to investors because higher or more stable census typically signals stronger revenue, better resource use, and clearer demand trends for planning and valuation.

Earnings Snapshot

Revenue: $4.213234 billion · Guidance included

Third quarter ended September 30, 2026

Revenue $4.213234 billion Compared with $3.334106 billion in Q3 2025

Income from continuing operations $100.802 million Compared with $37.488 million in Q3 2025

Adjusted EBITDA $227.759 million 42% growth from $160.443 million in Q3 2025

Guidance

Full-year 2026 revenue guidance of $15,900 million to $16,125 million and Adjusted EBITDA guidance of $850 million to $860 million. The guidance excludes Community Living and the effects of future closed acquisitions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What revenue did BTSG report for Q3 2026?

BrightSpring reported total revenue of $4.213234 billion for Q3 2026, versus $3.334106 billion for Q3 2025. Product revenue was $3.732428 billion and service revenue was $480.806 million.

What was BTSG's Q3 2026 Adjusted EBITDA?

BrightSpring reported Adjusted EBITDA of $227.759 million for Q3 2026, compared with $160.443 million in Q3 2025; the release reports 42% growth. Adjusted EBITDA is a non-GAAP measure, and the release reconciles it to net income from continuing operations.

What is BTSG's full-year 2026 financial guidance?

BrightSpring's 2026 guidance is revenue of $15,900 million to $16,125 million and Adjusted EBITDA of $850 million to $860 million. The growth ranges are 23.2% to 24.9% and 37.6% to 39.3%, respectively, versus full-year 2025 results excluding Community Living. Guidance also excludes the effects of future closed acquisitions.

How much Adjusted EBITDA is the Amedisys and LHC branches acquisition expected to contribute?

The Amedisys and LHC branches acquisition is expected to contribute approximately $35 million in Adjusted EBITDA in 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/30/2026 - 06:13 AM EDT Accepted by SEC EDGAR 10/30/2026 - 06:05 AM EDT Learn about SEC filing dates

false00018657820001865782btsg:SixPointSevenFivePercentageTangibleEquityUnitsMember2026-10-302026-10-3000018657822026-10-302026-10-300001865782us-gaap:CommonStockMember2026-10-302026-10-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2026

BrightSpring Health Services, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41938	82-2956404
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
805 N. Whittington Parkway
Louisville, Kentucky				40222
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 502 394-2100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		BTSG		The Nasdaq Stock Market LLC
6.75% Tangible Equity Units		BTSGU		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On October 30, 2026, BrightSpring Health Services, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.

The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release of BrightSpring Health Services, Inc., dated October 30, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			BRIGHTSPRING HEALTH SERVICES, INC.
Date:	October 30, 2026	By:	/s/ Jennifer Phipps
		Name: Title:	Jennifer Phipps Executive Vice President and Chief Financial Officer

BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance

LOUISVILLE, Ky., October 30, 2026 — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home- and community-based health services for complex populations, today announced financial results for the third quarter ended September 30, 2026, and increased full year 2026 Revenue and Adjusted EBITDA1 guidance.

Third Quarter 2026 Financial Highlights

(note: On March 30, 2026, BrightSpring completed the divestiture of the Community Living business and, as such, all financial results provided pertain to continuing operations)

•Net revenue of $4,213 million, up 26.4% compared to $3,334 million in the third quarter of 2025

•Gross profit of $519 million, up 32.3% compared to $392 million in the third quarter of 2025

•Net income from continuing operations of $101 million compared to $38 million in the third quarter of 2025

•Adjusted EBITDA1 of $228 million, up 42.0% compared to $160 million in the third quarter of 2025

•Leverage of 1.79x as of September 30, 2026, compared to leverage of 2.15x on June 30, 2026

"Our third quarter results again reflect the commitment of our team to patient care and operational execution across our Pharmacy and Provider businesses," said Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring. "We have a differentiated company, our value proposition for healthcare stakeholders is clear, and our confidence in the future remains high, supported by a broad set of process and growth drivers across a uniquely scaled and high-quality platform. As we progress through 2026, we believe that BrightSpring is well -positioned to make a greater and greater impact and deliver durable growth in 2027 and beyond."

1Adjusted EBITDA is a non-GAAP financial measure. Please see “Non-GAAP Financial Information” at the end of this press release for a reconciliation of Adjusted EBITDA to net income from continuing operations, the most directly comparable financial measure prepared in accordance with GAAP.

Key Financials2

	Three Months Ended						Nine Months Ended
	September 30, (Unaudited)						September 30, (Unaudited)
	2026		2025		%		2026		2025		%
($ in millions)
Pharmacy Solutions Revenue	$ 3,732		$ 2,967		26%		$ 10,311		$ 8,289		24%
Provider Services Revenue	481		367		31%		1,389		1,071		30%
Total Revenue	$ 4,213		$ 3,334		26%		$ 11,700		$ 9,360		25%

1

	Three Months Ended						Nine Months Ended
	September 30, (Unaudited)						September 30, (Unaudited)
	2026		2025		%		2026		2025		%
($ in millions)
Pharmacy Solutions Segment EBITDA	$ 202		$ 141		43%		$ 551		$ 381		45%
Provider Services Segment EBITDA	79		61		30%		220		168		31%
Total Segment EBITDA(1)	$ 281		$ 202		39%		$ 771		$ 550		40%
Corporate Costs	(53)		(41)		n.m.		(148)		(116)		n.m.
Total Company Adjusted EBITDA(1)	$ 228		$ 160		42%		$ 623		$ 434		44%

*n.m.: not meaningful

Business Metrics

	Three Months Ended						Nine Months Ended
	September 30, (Unaudited)						September 30, (Unaudited)
	2026		2025		%		2026		2025		%
Pharmacy Solutions
Prescriptions dispensed	10,949,875		10,793,219		2%		32,523,789		32,522,286		0%
Revenue per script ($)	340.86		274.89		24%		317.03		254.88		24%
Gross Profit per script ($)	28.86		22.76		27%		28.13		21.01		34%
Provider Services
Home Health Care average      daily census(3)	47,256		29,980		58%		46,898		30,212		55%
Rehab Care persons served(3)	7,574		6,932		9%		7,345		6,806		8%
Personal Care persons served	16,320		16,134		1%		16,253		16,046		1%

1Adjusted EBITDA and Segment EBITDA are non-GAAP financial measures. Please see “Non-GAAP Financial Information” and the end of this press release for a reconciliation of Adjusted EBITDA and Segment EBITDA to net income from continuing operations, the most directly comparable financial measure prepared in accordance with GAAP.

2Financial tables may not foot due to rounding.

3Effective July 1, 2026, the Company realigned its Rehab in Motion business from the Rehab Care sub-segment to the Home Health Care sub-segment to reflect how the business is managed. Prior period sub-segment information has been recast to conform to the current presentation. The change did not affect consolidated company or segment results. The impact on prior periods was not material.

2

Full Year 2026 Financial Guidance

For the full year 2026, BrightSpring is increasing Revenue and Adjusted EBITDA guidance, which excludes the Community Living business and the effects of any future closed acquisitions. All growth rates are shown as compared to the full year 2025 Revenue and Adjusted EBITDA results, excluding the Community Living business:

•Revenues of $15,900 million to $16,125 million, or 23.2% to 24.9% growth

oPharmacy Segment Revenue of $14,000 million to $14,200 million, or 22.3% to 24.1% growth

oProvider Segment Revenue of $1,900 million to $1,925 million, or 29.7% to 31.4% growth

•Total Adjusted EBITDA3 of $850 million to $860 million, or 37.6% to 39.3% growth

•The Amedisys and LHC branches acquisition is expected to contribute approximately $35 million in Adjusted EBITDA in 2026

3A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted EBITDA to GAAP net income from continuing operations cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

Webcast and Conference Call Details

The Company will host a conference call today, October 30th at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required to register online.

A live and archived webcast of the event will be available on the “Events & Presentations” section of the BrightSpring website at https://ir.brightspringhealth.com/. The Company has posted supplemental information on the third quarter 2026 results that it will reference during the conference call. The supplemental information can be found under the “Events & Presentations” on the Company’s investor relations page.

About BrightSpring Health Services

BrightSpring Health Services provides complementary home- and community-based health solutions for medically complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care, and rehabilitation, we provide comprehensive and more integrated care and clinical solutions in all 50 states to approximately 500,000 customers, clients and patients daily. BrightSpring has consistently demonstrated strong and industry-leading quality metrics across its services lines, while improving the health and quality of life for high-need individuals and reducing overall healthcare system costs.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating

3

information. In some cases, we have used words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” “target,” “guidance,” the negative version of these words, or similar terms and phrases to identify these forward-looking statements.

The forward-looking statements are based on management’s current expectations and are not historical facts or guarantees of future performance. The forward-looking statements relate to the future and are therefore subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:

•our operation in a highly competitive industry;

•our inability to maintain relationships with existing patient referral sources or establish new referral sources;

•changes to Medicare and Medicaid rates or methods governing Medicare and Medicaid payments for our services;

•cost containment initiatives of third-party payors, including post-payment audits;

•the implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may limit our market share and could adversely affect our revenues;

•changes in the case mix of patients, as well as payor mix and payment methodologies, and decisions and operations of third-party organizations;

•our reliance on federal and state spending, budget decisions, and continuous governmental operations which may fluctuate under different political conditions;

•changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement, which may negatively impact our profitability;

•changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing;

•reliance on the continual recruitment and retention of nurses, pharmacists, therapists, caregivers, direct support professionals, and other qualified personnel, including senior management;

•compliance with or changes to federal, state, and local laws and regulations that govern our employment practices, including minimum wage, living wage, and paid time-off requirements;

•fluctuation of our results of operations on a quarterly basis;

•harm caused by labor relation matters;

•limitations in our ability to control reimbursement rates received for our services if we are unable to maintain or reduce our costs to provide such services;

•delays in collection or non-collection of our accounts receivable, particularly during the business integration process;

•failure to manage our growth effectively, which may inhibit our ability to execute our business plan, maintain high levels of service and satisfaction or adequately address competitive challenges;

•our ability to identify, successfully complete and manage acquisitions, joint ventures, divestitures and other significant transactions and strategic initiatives;

•our ability to continue to provide consistently high quality of care;

4

•maintenance of our corporate reputation or the emergence of adverse publicity, including negative information on social media or changes in public perception of our services;

•contract continuance, expansion and renewal with our existing customers, including renewals at lower fee levels, customers declining to purchase additional services from us, or reduction in the services received from us pursuant to those contracts;

•effective investment in, implementation of improvements to and proper maintenance of the uninterrupted operation and data integrity of our information technology and other business systems;

•security breaches, loss of data, and other disruptions, which could compromise sensitive business or patient information; cause a loss of confidential patient data, employee data or personal information; or prevent access to critical information and thereby expose us to liability, litigation, and federal and state governmental inquiries and damage our reputation and brand;

•risks related to credit card payments and other payment methods;

•potential substantial malpractice or other similar claims;

•various risks related to governmental inquiries, regulatory actions, and whistleblower and other lawsuits, which may not be entirely covered by insurance;

•our current insurance program, which may expose us to unexpected costs, particularly if we incur losses not covered by our insurance or if claims or losses differ from our estimates;

•factors outside of our control, including those listed, which have required and could in the future require us to record an asset impairment of goodwill;

•a pandemic, epidemic, or outbreak of an infectious disease;

•inclement weather, natural disasters, acts of terrorism, riots, civil insurrection or social unrest, looting, protests, strikes, or street demonstrations;

•our inability to adequately protect our intellectual property rights;

•risks related to our compliance with our regulatory framework;

•the significant interests of KKR Stockholder may conflict with our stockholders’ interests in the future;

•our substantial indebtedness;

•significant changes in tax or trade policies, tariffs, or trade relations between the United States and other countries, such as the imposition of unilateral tariffs on imported products, including impacts on imported drug products, which could result in supply chain disruptions and significant increases in costs; and

•fluctuations in the amount and frequency of repurchases of our common stock.

The forward-looking statements included in this press release are made only as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law. These factors should not be construed as exhaustive, and should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make.

For additional information on these and other factors that could cause BrightSpring’s actual results to differ materially from expected results, please see our filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

5

Non-GAAP Financial Measures

This press release contains “non-GAAP financial measures,” including “EBITDA,” “Segment EBITDA,” “Adjusted EBITDA,” and “Adjusted EPS,” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with accounting principles generally accepted in the United States, or GAAP.

EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted EPS have been presented in this release as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP, because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management also believes that these measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted EPS to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures.

Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted EPS are non-GAAP measures of our financial performance and should not be considered as an alternative to net income as a measure of financial performance or any other performance measures derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use as they do not consider certain cash requirements such as tax payments, debt service requirements, total capital expenditures, and certain other cash costs that may recur in the future.

Management defines EBITDA as net income from continuing operations before income tax expense, interest expense, net and depreciation and amortization. Management defines Segment EBITDA as segment operating income before income tax expense, interest expense, net and depreciation and amortization. Management also defines Adjusted EBITDA as EBITDA, further adjusted to exclude non-cash share-based compensation, acquisition, integration and transaction-related costs, and restructuring and divestiture-related and other costs. Management also defines Adjusted EPS as Diluted EPS, further adjusted to exclude non-cash share-based compensation, acquisition, integration and transaction-related costs, restructuring and divestiture-related and other costs, and the income tax impact of the aforementioned adjustments.

The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. Please see the end of this press release for reconciliations of non-GAAP financial measures to the most directly comparable financial measure prepared in accordance with GAAP.

6

BrightSpring Contact:

Investor Relations:

David Deuchler, CFA

SVP, Strategic Finance & Investor Relations

Executive Director, BrightSpring Health Foundation

IR@brightspringhealth.com

917.209.5605

Media Contact:
Leigh White
Vice President, Communications & PR

leigh.white@brightspringhealth.com

502.630.7412

7

BrightSpring Health Services, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

September 30, 2026 and December 31, 2025

(In thousands, except share and per share data)

(Unaudited)

		September 30, 2026				December 31, 2025
Assets
Current assets:
Cash and cash equivalents		$	717,840			$	88,370
Accounts receivable, net of allowance for credit losses			1,216,377				989,719
Inventories			671,590				815,180
Prepaid expenses and other current assets			159,950				118,592
Current assets held for sale			—				882,189
Total current assets			2,765,757				2,894,050
Property and equipment, net of accumulated depreciation of $419,016 and $404,878 at     September 30, 2026 and December 31, 2025, respectively			213,530				204,689
Goodwill			2,537,128				2,545,673
Intangible assets, net of accumulated amortization			491,661				557,555
Operating lease right-of-use assets, net			169,977				171,632
Other assets			88,568				39,712
Total assets		$	6,266,621			$	6,413,311
Liabilities, Redeemable Noncontrolling Interests, and Equity
Current liabilities:
Trade accounts payable		$	1,232,288			$	1,217,946
Accrued expenses			390,967				333,024
Current portion of obligations under operating leases			46,296				42,936
Current portion of obligations under financing leases			5,988				6,794
Current portion of long-term debt			35,277				52,340
Current liabilities held for sale			—				195,994
Total current liabilities			1,710,816				1,849,034
Obligations under operating leases, net of current portion			133,569				135,420
Obligations under financing leases, net of current portion			11,072				14,544
Long-term debt, net of current portion			2,146,779				2,455,204
Deferred income taxes, net			10,336				6,178
Long-term liabilities			68,234				66,565
Total liabilities			4,080,806				4,526,945
Redeemable noncontrolling interests			9,200				11,227
Shareholders’ equity:
Common stock, $0.01 par value, 1,500,000,000 shares authorized, 198,814,320 and    192,124,125 shares issued and outstanding at September 30, 2026 and December 31,    2025 respectively		$	1,988			$	1,921
Preferred stock, $0.01 par value, 250,000,000 authorized, no shares issued and    outstanding at September 30, 2026 and December 31, 2025			—				—
Additional paid-in capital			2,021,881				1,954,482
Retained earnings (accumulated deficit)			138,572				(74,647	)
Accumulated other comprehensive income (loss)			14,099				(6,691	)
Total shareholders’ equity			2,176,540				1,875,065
Noncontrolling interest			75				74
Total equity			2,176,615				1,875,139
Total liabilities, redeemable noncontrolling interests, and equity		$	6,266,621			$	6,413,311

BrightSpring Health Services, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

For the three and nine months ended September 30, 2026 and 2025

(In thousands, except per share amounts)

(Unaudited)

		For the Three Months Ended								For the Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
Revenues:
Products		$	3,732,428			$	2,966,966			$	10,310,950			$	8,289,238
Services			480,806				367,140				1,389,145				1,070,695
Total revenues			4,213,234				3,334,106				11,700,095				9,359,933
Cost of goods			3,416,415				2,721,314				9,395,982				7,605,931
Cost of services			278,270				220,784				810,596				648,773
Gross profit			518,549				392,008				1,493,517				1,105,229
Selling, general, and administrative expenses			358,069				304,165				1,081,197				918,090
Operating income			160,480				87,843				412,320				187,139
Interest expense, net			31,038				38,235				106,532				118,776
Income from continuing operations before income taxes			129,442				49,608				305,788				68,363
Income tax expense			28,640				12,120				44,099				13,118
Income from continuing operations, net of income taxes			100,802				37,488				261,689				55,245
(Loss) income from discontinued operations, net of income taxes			(503	)			17,753				71,429				56,548
Net income			100,299				55,241				333,118				111,793
Net income (loss) attributable to noncontrolling interests included in    continuing operations			161				(595	)			(77	)			(1,793	)
Net income attributable to BrightSpring Health Services, Inc. and    subsidiaries		$	100,138			$	55,836			$	333,195			$	113,586
Net income per common share:
Basic income (loss) per share attributable to common shareholders:
Continuing operations		$	0.49			$	0.19			$	1.27			$	0.28
Discontinued operations		$	(0.01	)		$	0.08			$	0.35			$	0.28
Net income per share		$	0.48			$	0.27			$	1.62			$	0.56
Diluted income (loss) per share attributable to common shareholders:
Continuing operations		$	0.46			$	0.17			$	1.18			$	0.26
Discontinued operations		$	(0.01	)		$	0.09			$	0.33			$	0.26
Net income per share		$	0.45			$	0.26			$	1.51			$	0.52
Weighted average shares outstanding:
Basic			207,022				203,487				205,934				202,067
Diluted			220,226				217,982				220,972				218,519

BrightSpring Health Services, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

For the three and nine months ended September 30, 2026 and 2025

(In thousands)

(Unaudited)

		For the Three Months Ended								For the Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
Operating activities:
Net income		$	100,299			$	55,241			$	333,118			$	111,793
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			38,372				40,753				118,889				124,753
Impairment of long-lived assets			5,195				2,507				8,240				6,526
Change in fair value of contingent consideration, net			—				(3,269	)			—				(1,266	)
Payment of contingent consideration in excess of acquisition date fair value			—				(4,670	)			—				(6,170	)
Provision for credit losses			5,829				8,065				28,694				48,723
Amortization of deferred debt issuance costs			2,553				2,841				8,317				8,384
Share-based compensation			17,871				17,250				41,040				55,733
Deferred income taxes, net			6,484				14,374				(3,045	)			18,266
Loss (gain) on sale of discontinued operations			23				—				(101,845	)			—
Other			(771	)			(74	)			243				(335	)
Change in operating assets and liabilities, net of acquisitions and dispositions:
Accounts receivable			(83,372	)			(49,933	)			(235,949	)			(162,689	)
Prepaid expenses and other current assets			45,075				446				(41,057	)			24,857
Inventories			(96,581	)			(13,752	)			143,408				(2,279	)
Trade accounts payable			142,423				(10,441	)			54,920				42,836
Accrued expenses			19,235				60,702				47,186				17,212
Other assets and liabilities			1,687				(12,104	)			(30,978	)			(27,734	)
Net cash provided by operating activities		$	204,322			$	107,936			$	371,181			$	258,610
Investing activities:
Purchases of property and equipment		$	(22,090	)		$	(15,762	)		$	(72,666	)		$	(57,819	)
Acquisitions of businesses			(1,929	)			(1,554	)			(44,132	)			(8,308	)
Proceeds from sale of discontinued operations			—				—				810,908				—
Other			827				(6,445	)			1,893				(5,068	)
Net cash (used in) provided by investing activities		$	(23,192	)		$	(23,761	)		$	696,003			$	(71,195	)
Financing activities:
Long-term debt repayments			(11,809	)			(14,213	)		$	(332,300	)		$	(37,933	)
Repayments of the Revolving Credit Facility, net			—				—				—				(63,300	)
Payments of debt issuance costs			—				—				(3,378	)			—
Repurchases of shares of common stock			—				—				(120,000	)			—
Proceeds from shares issued under share-based compensation plan			4,841				5,619				37,256				14,681
Taxes paid related to net share settlement of equity awards			(4,941	)			(1,071	)			(11,548	)			(5,583	)
Purchase of redeemable noncontrolling interest			—				—				(267	)			(5,100	)
Payments of financing lease obligations			(1,762	)			(3,442	)			(7,584	)			(10,133	)
Net cash used in financing activities		$	(13,671	)		$	(13,107	)		$	(437,821	)		$	(107,368	)
Net increase in cash and cash equivalents			167,459				71,068				629,363				80,047
Cash and cash equivalents at beginning of period			550,381				70,232				88,477				61,253
Cash and cash equivalents at end of period		$	717,840			$	141,300			$	717,840			$	141,300
Cash and cash equivalents included in assets held for sale at end of period			—				956				—				956
Cash and cash equivalents included in continuing operations at end of period		$	717,840			$	140,344			$	717,840			$	140,344

BrightSpring Health Services, Inc. and Subsidiaries

Reconciliation of Segment EBITDA

For the three and nine months ended September 30, 2026 and 2025

(Unaudited)

The following table reconciles net income from continuing operations to Segment EBITDA:

($ in thousands)		For the Three Months Ended								For the Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
Net income from continuing operations		$	100,802			$	37,488			$	261,689			$	55,245
Segment depreciation and amortization			30,794				33,791				97,367				102,275
Expenses not allocation at segment level:
Selling, general, and administrative expenses			82,080				73,060				239,681				239,047
Depreciation and amortization			7,578				6,962				21,522				21,149
Interest expense, net			31,038				38,235				106,532				118,776
Income tax expense			28,640				12,120				44,099				13,118
Total Segment EBITDA		$	280,932			$	201,656			$	770,890			$	549,610

BrightSpring Health Services, Inc. and Subsidiaries

Reconciliation of EBITDA and Adjusted EBITDA

For the three and nine months ended September 30, 2026 and 2025

(Unaudited)

The following table reconciles net income from continuing operations to EBITDA and Adjusted EBITDA:

($ in thousands)		For the Three Months Ended								For the Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
Net income from continuing operations		$	100,802			$	37,488			$	261,689			$	55,245
Income tax expense			28,640				12,120				44,099				13,118
Interest expense, net			31,038				38,235				106,532				118,776
Depreciation and amortization			38,372				40,753				118,889				123,424
EBITDA		$	198,852			$	128,596			$	531,209			$	310,563
Non-cash share-based compensation (1)			17,871				14,173				50,475				46,155
Acquisition, integration, and transaction-related costs (2)			2,855				5,462				15,585				34,811
Restructuring and divestiture-related and other costs (3)			8,181				12,212				25,756				42,493
Total adjustments		$	28,907			$	31,847			$	91,816			$	123,459
Adjusted EBITDA		$	227,759			$	160,443			$	623,025			$	434,022

(1)Represents non-cash share-based compensation to certain members of our management and full-time employees.

(2)Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, finance and accounting diligence and documentation; costs associated with the integration of acquisitions, including any facility consolidation, integration travel, or severance; and costs associated with other planned, completed, or terminated non-routine transactions.

(3)Represents costs associated with restructuring-related activities, including closure, and related license impairment, and severance expenses associated with certain enterprise-wide or significant business line cost-savings measures.

BrightSpring Health Services, Inc. and Subsidiaries

Reconciliation of Adjusted EPS

For the three and nine months ended September 30, 2026 and 2025

(Unaudited)

The following table reconciles diluted EPS to Adjusted EPS:

(shares in thousands)		For the Three Months Ended								For the Nine Months Ended
		September 30,								September 30,
		2026				2025				2026				2025
Diluted EPS		$	0.46			$	0.17			$	1.18			$	0.26
Non-cash share-based compensation (1)			0.08				0.07				0.23				0.21
Acquisition, integration, and transaction-related costs (1)			0.01				0.03				0.07				0.16
Restructuring and divestiture-related and other costs (1)			0.04				0.06				0.12				0.19
Income tax impact on adjustments (2)			(0.05	)			(0.03	)			(0.23	)			(0.13	)
Adjusted EPS		$	0.54			$	0.30			$	1.37			$	0.69
Weighted average common shares outstanding used in calculating      diluted U.S. GAAP net income per share			220,226				217,982				220,972				218,519
Weighted average common shares outstanding used in calculating      diluted Non-GAAP income per share			220,226				217,982				220,972				218,519

(1) This adjustment reflects the per share impact of the adjustment reflected within the definition of Adjusted EBITDA.

(2) The income tax impact of non-GAAP adjustments is calculated using the estimated tax rate for the respective non-GAAP adjustment. For all periods presented, the income tax impact on adjustments is inclusive of a discrete tax benefit related to share-based compensation.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 1.0 MB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 44.5 KB